Electroporation Explained: Mechanism & Applications in Cell Transformation

Recombinant DNA technology diagram: DNA and vector cut with same restriction enzyme, joined to form recombinant DNA, introduced into host cell via transformation, host produces protein. Gene isolation methods: PCR (known sequence), restriction enzymes (known sequence), mRNA to DNA conversion (expressed genes). Transformation methods: Physical (microinjection, biolistics, electroporation), Chemical (calcium phosphate, lipofection), Biological (viral transfection, Agrobacterium), Physicochemical (heat shock with calcium chloride). Method selection depends on cell type and available technology.

Lipofection uses liposomes (fatty bubbles) to deliver DNA into cells. The process involves mixing DNA with lipofectamine reagent, which forms complexes that fuse with cell membranes. The DNA is then released into the cytoplasm where it can enter the nucleus and be transcribed. Incubation time allows liposomes to form properly around the DNA before adding to cells.

Gene transfer methods include transformation (DNA uptake by bacterial cells, facilitated by calcium chloride making cells more permeable), transfection (DNA introduction into eukaryotic cells using chemical methods like calcium phosphate, DEAE dextran, or PEG, or physical methods like electroporation, microinjection, and lipofection), and transduction (DNA transfer via viral vectors); the choice of method depends on the host cell type and experimental requirements.

Lipofection is a gene transfer technique that uses liposomes—spherical structures composed of phospholipid bilayers containing an empty central space—to deliver nucleic acids into host cells; the process involves creating liposome-nucleic acid complexes that fuse with host cell membranes, causing membrane rupture and allowing DNA to enter the host cell cytoplasm and eventually the nucleus, forming recombinant DNA within recombinant cells.

To simplify CRISPR delivery to primary human islets, researchers developed an electroporation-based approach using pre-formed Cas9-RNP complexes. This method eliminates the need for lentiviral vector construction and avoids genomic integration, providing higher simplicity, scalability, and safety. Efficiency of approximately 40% was achieved for PDX1 targeting. For multiplex targeting, dual-guide RNPs targeting both promoter and enhancer regions of PCSK1 (which converts proinsulin to mature insulin) showed synergistic effects—targeting either region alone reduced glucose-responsive PCSK1 expression at high glucose concentrations, while combined targeting impaired expression at both low and high glucose levels. This demonstrates the power of multiplex CRISPR approaches for studying gene regulatory networks.

The non-viral genome editing workflow for primary T-cells involves several key steps: isolating and stimulating T-cells two days before electroporation; forming RNP complexes with Cas9 endonuclease protein and guide RNA; mixing with HDR donor templates; and performing electroporation taking approximately one and a half hours. After electroporation, cells are expanded for one to two additional weeks. Viability is measured two days post-electroporation, while GFP expression is measured at day four. Studies demonstrated near 50% GFP expression efficiency in both CD4+ and CD8+ primary human T-cells using RNP with double-stranded DNA donor templates, with average efficiencies of 33.7% and 40.3% respectively for Rab11a targeting.

Invitro transcribed single guide RNAs can trigger cellular innate immune responses, causing significant cell death and inducing interferon-stimulated genes (500-fold increase) compared to minimal induction with synthetic two-part RNA oligos. Direct delivery of Cas9 protein complexed with guide RNA as a ribonucleoprotein (RNP) complex offers superior advantages: protection of RNA from degradation, higher editing efficiency than plasmid delivery, no DNA integration events, tight temporal control of Cas9 expression, reduced off-target effects from excess Cas9, and reduced mosaicism risk in embryo studies. RNP delivery achieves comparable editing efficiencies to stable Cas9 cell lines while maintaining the flexibility to test diverse cell types including primary cells and embryonic systems.

Naked ribonucleoprotein (RNP) complexes consist of pre-assembled Cas9 protein bound to guide RNA, offering the tightest temporal control over gene editing. Without protective carriers, RNPs face rapid degradation by cellular nucleases, limiting Cas9 activity duration and reducing safety risks like insertional mutagenesis. Two delivery methods exist: dual RNA (separate guide RNA and Cas9 mRNA) and pre-complexed RNP. Vertex achieves 80% editing efficiency in bone marrow stem cells using electroporation for Casgevy manufacturing. However, in vivo naked RNP delivery faces challenges: poor cellular uptake, rapid degradation, and limited range (effective only within hundreds of micrometers from injection sites).

This video demonstrates a complete workflow for conducting a PDCD1 gene knockout in primary T cells using CRISPR-Cas9 technology with the Invitrogen Neon Next electroporation system. The process involves: (1) designing the experiment using the TrueDesign genome editor software to select appropriate gRNAs based on performance scores and off-target predictions; (2) preparing cells by isolating peripheral blood mononuclear cells, activating them with CD3/CD28 beads for 72 hours, and removing activation beads; (3) preparing RMP complexes by mixing TrueCut High-Fidelity Cas9 protein with resuspended gRNAs and resuspension buffer; (4) performing electroporation using optimized parameters (1600V, 10ms, 3 pulses) with careful attention to preventing bubble formation; (5) validating knockout success through flow cytometry analysis using PE-conjugated anti-PDCD1 antibodies to quantify the percentage of PDCD1-negative cells compared to control samples.

The human body is fundamentally electrical, with cell membranes, receptors, and DNA functioning as transducers, making electrical therapies a logical approach. Electroporation is the phenomenon where applying electrical pulses to cell membranes creates temporary pores. When voltage is applied across electrodes separated by 10 nanometers, an electric field of approximately 10^6 volts per centimeter is created, causing membrane breakdown and pore formation. Electrochemotherapy combines electrical pulses with chemotherapy drugs, achieving 1,000-fold enhancement of drug uptake and allowing lower drug doses with fewer side effects. The UK National Institute for Health and Care Excellence approved electrochemotherapy in 2014 for basal cell carcinoma, with response rates of 100% compared to 40-54% for traditional chemotherapy. The technique can be applied to breast cancer, liver metastasis, and head and neck cancers. Different electrode configurations are used based on tumor characteristics: flat electrodes for flat tumors, and needle electrodes for bulky tumors.

Electroporation is primarily indicated for pancreatic cancer patients who cannot undergo surgery due to local invasion of surrounding structures. It is also used for liver tumors near critical blood vessels, prostate cancer, and lung cancer. The treatment preserves critical structures like blood vessels and bile ducts, has the lowest surgical complication risk, and allows faster recovery. The procedure uses imaging guidance to insert needles through safe tissue windows directly to tumors. Post-procedure, patients may experience temporary discomfort and small hematomas for one to two days. Electroporation is performed by interventional radiologists and represents an important option in the comprehensive arsenal of cancer treatments.

Electrochemotherapy serves as a salvage treatment for patients who have exhausted all other treatment options, primarily those with cutaneous metastases from breast cancer and in-transit melanoma metastases. The treatment uses two primary drugs: Bleomycin, a large polar molecule that normally only reaches 0.1% of its target DNA but achieves dramatically increased cellular uptake through electrical fields, and Cisplatin, a smaller polar molecule with approximately 20-40 times enhanced transport efficiency compared to standard conditions. Treatment efficacy correlates strongly with tumor size, with excellent responses in small tumors (a few millimeters) and multiple sessions required for tumors exceeding three centimeters. The procedure involves applying electrical pulses through needles inserted into tumors, with standardized protocols including eight pulses of 0.1 milliseconds duration.

Electroporation is a clinical therapy using electric fields to permeabilize cell membranes, enhancing chemotherapy drug uptake. The cell can be modeled as an electrical circuit with a capacitor (cell membrane) and resistors (cytoplasm and external tissue). Tissue electrical properties depend on cell size, concentration, and extracellular matrix composition. The therapy can be reversible or irreversible depending on voltage amplitude, pulse frequency, and number of pulses. Clinical applications include melanoma, adenocarcinoma, and subcutaneous tumors. The first guidelines were issued in 2000, with standard operating procedures established by 2006. Clinical studies on breast cancer recurrence showed 89% overall response rate and nearly 60% complete response rate. Standard protocols involve specific voltage amplitudes (commonly 700 volts) depending on needle distance.

Electroporation uses brief electrical pulses to temporarily increase cell membrane permeability, enhancing drug delivery by up to 1,000-fold. Cell membranes function as capacitors; when voltage exceeds critical thresholds, dielectric breakdown creates pores allowing molecules to enter. Two main therapies exist: electrochemotherapy (combining chemotherapy with electrical pulses) and irreversible electroporation (direct cell destruction). Electrochemotherapy uses bleomycin and cisplatin, achieving 77% response rates versus 19-56% for conventional chemotherapy alone. Complete response rates reach 98.7-100%. Advantages include excellent local tumor control (up to 90%), pain relief for advanced tumors, minimal damage to healthy tissue, reduced chemotherapy doses, no protein denaturation, high safety profile, good cost-benefit ratio, and outpatient treatment. Clinical case studies demonstrate effectiveness in difficult-to-treat cancers: recurrent breast cancer, buccal mucosa carcinoma, and tongue cancer achieved significant tumor reduction and quality-of-life improvements. Irreversible electroporation offers particular value for liver cancer, destroying cells without thermal damage to preserve organ structure. Computational modeling enables simulation of cell membrane behavior and electric field distribution before clinical application.

Irreversible Electroporation (IRE) is a non-thermal ablation technique that uses short electrical pulses (up to 3000V) to create pores in tumor cell membranes, destroying cancer cells while preserving blood vessels and nerves; it is particularly valuable for locally advanced pancreatic tumors that cannot be completely removed surgically, offering a treatment option for approximately 85% of patients who are not candidates for primary surgery, with the procedure typically lasting 2-3 hours and requiring a 5-7 day hospital stay.

IRE is a non-thermal ablation technique using electrical pulses to create permanent cell membrane pores. Unlike thermal ablation, IRE can treat tumors near critical structures like blood vessels and bile ducts. Applications include pancreatic cancer (locally advanced or borderline cases) and HCC lesions near central bile ducts. IRE does not create a visible necrosis zone, making assessment more challenging.

Irreversible electroporation (IRE) is a non-thermal ablation technology that uses high-voltage electrical pulses to create irreversible pores in cell membranes, causing apoptosis while preserving critical structures like bile ducts and blood vessels, making it particularly suitable for treating locally advanced hepatocellular carcinoma and pancreatic adenocarcinoma that are not candidates for surgical resection.

Irreversible electroporation (IRE), also known as NanoKnife technology, is a minimally invasive surgical ablation method that destroys cancerous tissue by applying extremely short electrical pulses (less than 100 millionths of a second) to create permanent nanosized pores in cell membranes, inducing natural cell death without using thermal energy; this non-thermal approach preserves surrounding critical structures like nerves and blood vessels while effectively treating soft tissue lesions in a fraction of the time required by traditional thermal ablation methods.

Irreversible electroporation (NanoKnife) represents a novel non-thermal ablation technique receiving FDA approval in 2011 for soft tissue ablation. Unlike thermal methods (cryotherapy, HIFU) that destroy tissue through heat or cold, IRE uses electric current to create permanent pores in cell membranes, triggering apoptosis without thermal damage. The procedure employs real-time MRI-ultrasound fusion guidance to place electrodes precisely around tumors. This non-thermal mechanism theoretically preserves surrounding vital structures including urethra, neurovascular bundles, and sphincter muscles.